IGRA prevalence study
A cross-sectional study to determine IGRA positivity rate to assess eligibility for participation in tuberculosis (TB) vaccine efficacy trials
IAVI
The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug resistant tuberculosis in India and China
We investigated the epidemiologic impact, cost-effectiveness, and budget impact of hypothetical novel prophylactic prevention of disease TB vaccines on RR/MDR-TB in China and India.
TB vaccine advocacy roadmap
The TB Vax ARM represents a global coalition of TB stakeholders, including TB survivors, civil society organizations, and non-profits, invested in TB vaccine advocacy and research, and seeks to provide coordinated advocacy efforts that are complementary to ongoing TB vaccine R&D and policy efforts. The TB Vax ARM holds regular virtual calls with partners and guest speakers from around the world. WGNV coordinates with the TB Vax ARM on global advocacy activities. For more information go to: https://newtbvaccines.org/take-action/
Bridging the gap: evaluating high TB burden country data needs to support the potential introduction of TB vaccines for adolescents and adults: a workshop report
A workshop to asked high TB burden country experts about what epidemiological, impact, feasibility and acceptability data they anticipated they would need to guide TB vaccine introduction.
The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study
We estimated the impact of novel tuberculosis vaccines in low-income and middle-income countries (LMICs) in several delivery scenarios.
The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study
We assessed future costs, cost-savings, and cost-effectiveness of introducing novel TB vaccines in low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies.